Chen Wei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Chen Wei has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Dongbing Liu
BGI Genomics, Shenzhen, China
17 shared publications - Guangyu Ding
Department of Liver Surgery & Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China
17 shared publications - Guohe Song
Department of Liver Surgery and Transplantation, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China
17 shared publications - Haorong Lu
China National Genebank, BGI-Shenzhen, Shenzhen, China
17 shared publications - Jia Fan
Fudan University
17 shared publications - Jian Lin
Fudan University 2 Shanghai
17 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Metronomic Chemotherapy Induces Metabolic Reprogramming in Cancer Cells That Modulates Mature Regulatory Dendritic Cell Function to Stimulate Antitumor Immunity
MCM reprograms amino acid metabolism in the tumor microenvironment, leading to PD-L1low mregDC differentiation and boosted antitumor responses
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Metronomic Chemotherapy Induces Metabolic Reprogramming in Cancer Cells That Modulates Mature Regulatory Dendritic Cell Function to Stimulate Antitumor Immunity
MCM reprograms amino acid metabolism in the tumor microenvironment, leading to PD-L1low mregDC differentiation and boosted antitumor responses
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Metronomic Chemotherapy Induces Metabolic Reprogramming in Cancer Cells That Modulates Mature Regulatory Dendritic Cell Function to Stimulate Antitumor Immunity
Asparagine directly binds to AXL on dendritic cells, inhibiting PD-L1 expression and promoting T cell-mediated tumor control
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Metronomic Chemotherapy Induces Metabolic Reprogramming in Cancer Cells That Modulates Mature Regulatory Dendritic Cell Function to Stimulate Antitumor Immunity
Asparagine directly binds to AXL on dendritic cells, inhibiting PD-L1 expression and promoting T cell-mediated tumor control
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Metronomic Chemotherapy Induces Metabolic Reprogramming in Cancer Cells That Modulates Mature Regulatory Dendritic Cell Function to Stimulate Antitumor Immunity
MCM enhances ATF4 activation in tumor cells, which facilitates mregDC-mediated formation of central memory T cells, improving long-term protection
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Metronomic Chemotherapy Induces Metabolic Reprogramming in Cancer Cells That Modulates Mature Regulatory Dendritic Cell Function to Stimulate Antitumor Immunity
MCM enhances ATF4 activation in tumor cells, which facilitates mregDC-mediated formation of central memory T cells, improving long-term protection
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Metronomic Chemotherapy Induces Metabolic Reprogramming in Cancer Cells That Modulates Mature Regulatory Dendritic Cell Function to Stimulate Antitumor Immunity
MCM sustains CD8+ central memory T cells in tumor-draining lymph nodes by downregulating PD-L1 expression on mregDCs, enhancing antitumor immunity
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Metronomic Chemotherapy Induces Metabolic Reprogramming in Cancer Cells That Modulates Mature Regulatory Dendritic Cell Function to Stimulate Antitumor Immunity
MCM sustains CD8+ central memory T cells in tumor-draining lymph nodes by downregulating PD-L1 expression on mregDCs, enhancing antitumor immunity
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Metronomic Chemotherapy Induces Metabolic Reprogramming in Cancer Cells That Modulates Mature Regulatory Dendritic Cell Function to Stimulate Antitumor Immunity
MCM-induced PD-L1low mregDCs via ATF4-ASNS signaling serve as a predictor for favorable outcomes in cancer patients
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Metronomic Chemotherapy Induces Metabolic Reprogramming in Cancer Cells That Modulates Mature Regulatory Dendritic Cell Function to Stimulate Antitumor Immunity
MCM-induced PD-L1low mregDCs via ATF4-ASNS signaling serve as a predictor for favorable outcomes in cancer patients
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Metronomic Chemotherapy Induces Metabolic Reprogramming in Cancer Cells That Modulates Mature Regulatory Dendritic Cell Function to Stimulate Antitumor Immunity
The efficacy of chemotherapy depends partly on the ability to induce antitumor immunity. A better understanding of how different chemotherapy modes mediate antitumor immune responses could provide insights for developing optimized treatment modalities. In this study, we demonstrated that metronomic chemotherapy (MC), a mode of frequent and regular administration of chemotherapeutic drugs at lower doses, induced robust CD8+ T cell–dependent antitumor immune memory by modulating the activity of mature regulatory dendritic cells (mregDCs). Mechanistically, by imposing more frequent stress on tumor cells, MC induced sustained activation of activating transcription factor 4 (ATF4), leading to metabolic reprogramming of tumor cells and enhanced asparagine (Asn) release into the tumor microenvironment. Functioning as a ligand, Asn directly bound to AXL receptor tyrosine kinase (AXL) on mregDCs, inhibiting AXL kinase activity and downregulating programmed death-ligand 1 (PD-L1) expression. Consequently, mregDCs with reduced PD-L1 expression fostered the generation of more memory-like CD8+ T cells during their interactions. Overall, this study unveils critical biological events driving antitumor immune memory formation under therapeutic stress and provides a rationale for optimizing chemotherapy modalities.Significance:Metronomic chemotherapy enhances antitumor immunity by rewiring tumor cell metabolism to reprogram mature regulatory dendritic cells and foster memory CD8+ T-cell formation, providing insights for enhancing treatment efficacy.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Metronomic Chemotherapy Induces Metabolic Reprogramming in Cancer Cells That Modulates Mature Regulatory Dendritic Cell Function to Stimulate Antitumor Immunity
The efficacy of chemotherapy depends partly on the ability to induce antitumor immunity. A better understanding of how different chemotherapy modes mediate antitumor immune responses could provide insights for developing optimized treatment modalities. In this study, we demonstrated that metronomic chemotherapy (MC), a mode of frequent and regular administration of chemotherapeutic drugs at lower doses, induced robust CD8+ T cell–dependent antitumor immune memory by modulating the activity of mature regulatory dendritic cells (mregDCs). Mechanistically, by imposing more frequent stress on tumor cells, MC induced sustained activation of activating transcription factor 4 (ATF4), leading to metabolic reprogramming of tumor cells and enhanced asparagine (Asn) release into the tumor microenvironment. Functioning as a ligand, Asn directly bound to AXL receptor tyrosine kinase (AXL) on mregDCs, inhibiting AXL kinase activity and downregulating programmed death-ligand 1 (PD-L1) expression. Consequently, mregDCs with reduced PD-L1 expression fostered the generation of more memory-like CD8+ T cells during their interactions. Overall, this study unveils critical biological events driving antitumor immune memory formation under therapeutic stress and provides a rationale for optimizing chemotherapy modalities.Significance:Metronomic chemotherapy enhances antitumor immunity by rewiring tumor cell metabolism to reprogram mature regulatory dendritic cells and foster memory CD8+ T-cell formation, providing insights for enhancing treatment efficacy.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Metronomic Chemotherapy Induces Metabolic Reprogramming in Cancer Cells That Modulates Mature Regulatory Dendritic Cell Function to Stimulate Antitumor Immunity
Metronomic capecitabine (MCM) promotes antitumor memory by altering immune cell populations and inhibiting tumor growth in rechallenge experiments across multiple mouse models
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Metronomic Chemotherapy Induces Metabolic Reprogramming in Cancer Cells That Modulates Mature Regulatory Dendritic Cell Function to Stimulate Antitumor Immunity
Metronomic capecitabine (MCM) promotes antitumor memory by altering immune cell populations and inhibiting tumor growth in rechallenge experiments across multiple mouse models
- 5 March 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (11) , 2793-2809
Metronomic Chemotherapy Induces Metabolic Reprogramming in Cancer Cells That Modulates Mature Regulatory Dendritic Cell Function to Stimulate Antitumor Immunity
The efficacy of chemotherapy depends partly on the ability to induce antitumor immunity. A better understanding of how different chemotherapy modes mediate antitumor immune responses could provide insights for developing optimized treatment modalities. In this study, we demonstrated that metronomic chemotherapy (MC), a mode of frequent and regular administration of chemotherapeutic drugs at lower doses, induced robust CD8+ T cell–dependent antitumor immune memory by modulating the activity of mature regulatory dendritic cells (mregDCs). Mechanistically, by imposing more frequent stress on tumor cells, MC induced sustained activation of activating transcription factor 4 (ATF4), leading to metabolic reprogramming of tumor cells and enhanced asparagine (Asn) release into the tumor microenvironment. Functioning as a ligand, Asn directly bound to AXL receptor tyrosine kinase (AXL) on mregDCs, inhibiting AXL kinase activity and downregulating programmed death-ligand 1 (PD-L1) expression. Consequently, mregDCs with reduced PD-L1 expression fostered the generation of more memory-like CD8+ T cells during their interactions. Overall, this study unveils critical biological events driving antitumor immune memory formation under therapeutic stress and provides a rationale for optimizing chemotherapy modalities. Significance: Metronomic chemotherapy enhances antitumor immunity by rewiring tumor cell metabolism to reprogram mature regulatory dendritic cells and foster memory CD8+ T-cell formation, providing insights for enhancing treatment efficacy.
- 5 March 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (11) , 2793-2809
Metronomic Chemotherapy Induces Metabolic Reprogramming in Cancer Cells That Modulates Mature Regulatory Dendritic Cell Function to Stimulate Antitumor Immunity
The efficacy of chemotherapy depends partly on the ability to induce antitumor immunity. A better understanding of how different chemotherapy modes mediate antitumor immune responses could provide insights for developing optimized treatment modalities. In this study, we demonstrated that metronomic chemotherapy (MC), a mode of frequent and regular administration of chemotherapeutic drugs at lower doses, induced robust CD8+ T cell–dependent antitumor immune memory by modulating the activity of mature regulatory dendritic cells (mregDCs). Mechanistically, by imposing more frequent stress on tumor cells, MC induced sustained activation of activating transcription factor 4 (ATF4), leading to metabolic reprogramming of tumor cells and enhanced asparagine (Asn) release into the tumor microenvironment. Functioning as a ligand, Asn directly bound to AXL receptor tyrosine kinase (AXL) on mregDCs, inhibiting AXL kinase activity and downregulating programmed death-ligand 1 (PD-L1) expression. Consequently, mregDCs with reduced PD-L1 expression fostered the generation of more memory-like CD8+ T cells during their interactions. Overall, this study unveils critical biological events driving antitumor immune memory formation under therapeutic stress and provides a rationale for optimizing chemotherapy modalities. Significance: Metronomic chemotherapy enhances antitumor immunity by rewiring tumor cell metabolism to reprogram mature regulatory dendritic cells and foster memory CD8+ T-cell formation, providing insights for enhancing treatment efficacy.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Geospatial Immune Heterogeneity Reflects the Diverse Tumor–Immune Interactions in Intrahepatic Cholangiocarcinoma
Supplementary Table from Geospatial Immune Heterogeneity Reflects the Diverse Tumor–Immune Interactions in Intrahepatic Cholangiocarcinoma
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Geospatial Immune Heterogeneity Reflects the Diverse Tumor–Immune Interactions in Intrahepatic Cholangiocarcinoma
Supplementary Table from Geospatial Immune Heterogeneity Reflects the Diverse Tumor–Immune Interactions in Intrahepatic Cholangiocarcinoma